Extended Data Fig. 7: Contributions of host receptors and LPS acylation states to immune activation.
From: Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses
a, NF-kB reporter human THP-1 cells that do not (WT) or do over-express CD14 and TLR4 (CD14/TLR4-OE) were incubated with the indicated doses of hexa- or penta-acylated LPS for 24 h. Representative data from n = 3 biological replicates are shown from one of two experimental repeats. No significant differences between WT and CD14/TLR4-OE were calculated by two-tailed Mann-Whitney tests comparing equivalent doses and types of LPS. b, WT NF-kB reporter THP-1 cells were incubated with the indicated doses of hexa-acylated LPS and polymyxin B (PMB) for 24 h. NF-kB activation is expressed as a percentage of maximum. The means of n = 2 biological replicates are plotted in representative plots from one of three experimental repeats. Mouse RAW 264.7 macrophages were incubated with the indicated doses of hexa- or penta-acylated LPS without (c) or with (d) indicated concentrations of polymyxin B (PMB) for 24 h. Cytokine secretion was measured by cytometric bead arrays from culture supernatants. c, IL-6 (top) and TNF-α (bottom) secretion after 24 h of the indicated doses of hexa- or penta-acylated LPS. d, IL-6 (top) and TNF- α (bottom) secretion after 24 h of the indicated doses of hexa-acylated LPS and PMB. The means of n = 2 biological replicates are plotted in representative plots from one of three experimental repeats. For all plots, data are presented as mean ± SD.
